These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16270126)

  • 1. A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation.
    Atalla A; Maiolino A; Guimarães MA; Guimarães AC; Nucci M
    Braz J Infect Dis; 2005 Aug; 9(4):330-5. PubMed ID: 16270126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.
    Dignani MC; Mykietiuk A; Michelet M; Intile D; Mammana L; Desmery P; Milone G; Pavlovsky S
    Bone Marrow Transplant; 2002 Feb; 29(3):263-7. PubMed ID: 11859400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
    Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
    Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients.
    Liesveld JL; Abboud CN; Ifthikharuddin JJ; Lancet JE; Wedow LA; Oliva J; Stamm CG; Nichols D
    Biol Blood Marrow Transplant; 2002; 8(12):662-5. PubMed ID: 12523578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.
    Erard V; Wald A; Corey L; Leisenring WM; Boeckh M
    J Infect Dis; 2007 Jul; 196(2):266-70. PubMed ID: 17570114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation.
    Shepp DH; Dandliker PS; Flournoy N; Meyers JD
    J Antimicrob Chemother; 1985 Sep; 16(3):389-95. PubMed ID: 2997101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage.
    Alsuhebany N; Alshehri B; Aldairem A; Aleissa MM; AlQahtani H; Albarqi K; Almotairi B; AlAmri M; Alanazi W; Alay S; Alahmari B; Alzahrani M
    Bone Marrow Transplant; 2024 Jul; 59(7):1043-1045. PubMed ID: 38627451
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
    Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
    J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.
    Kawamura K; Hayakawa J; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Hematol; 2015 Aug; 102(2):230-7. PubMed ID: 25990803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients.
    Warkentin DI; Epstein JB; Campbell LM; Yip JG; Cox VC; Ransier A; Barnett MJ; Marra F
    Ann Pharmacother; 2002 Oct; 36(10):1525-31. PubMed ID: 12243600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.
    Orlowski RZ; Mills SR; Hartley EE; Ye X; Piantadosi S; Ambinder RF; Gore SD; Miller CB
    Leuk Lymphoma; 2004 Nov; 45(11):2215-9. PubMed ID: 15512809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation.
    Wade JC; Newton B; Flournoy N; Meyers JD
    Ann Intern Med; 1984 Jun; 100(6):823-8. PubMed ID: 6326632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
    Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
    Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients.
    Kim JH; Schaenman JM; Ho DY; Brown JM
    Biol Blood Marrow Transplant; 2011 Feb; 17(2):259-64. PubMed ID: 20615475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.
    Ariza-Heredia EJ; Chemaly RF; Shahani LR; Jang Y; Champlin RE; Mulanovich VE
    Transpl Int; 2018 Jun; 31(6):639-648. PubMed ID: 29464765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.
    Sawtell NM; Thompson RL; Stanberry LR; Bernstein DI
    J Infect Dis; 2001 Oct; 184(8):964-71. PubMed ID: 11574910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts.
    Jiang J; Zhu Y; Jian G; Zhu W
    Chin Med J (Engl); 1995 Jun; 108(6):459-61. PubMed ID: 7555258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
    Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
    Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.